 | Denali Therapeutics Inc (NASDAQ:DNLI) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 4 at 3:59 AM |
| $10.86 Million in Sales Expected for Denali Therapeutics Inc (NASDAQ:DNLI) This Quarter
www.americanbankingnews.com - October 3 at 10:21 AM |
| Denali Therapeutics Inc (NASDAQ:DNLI) Expected to Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - October 1 at 3:33 PM |
| Denali Therapeutics Inc to Post Q3 2019 Earnings of ($0.64) Per Share, Wedbush Forecasts (NASDAQ:DNLI)
www.americanbankingnews.com - September 30 at 1:05 AM |
 | Citi upgrades AbbVie in premarket analyst action
seekingalpha.com - September 26 at 8:57 AM |
| Denali Therapeutics (NASDAQ:DNLI) Receives New Coverage from Analysts at Wedbush
www.americanbankingnews.com - September 25 at 8:46 PM |
| Leerink likes Acadia Pharma in premarket analyst action
seekingalpha.com - September 13 at 8:52 AM |
 | Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website
finance.yahoo.com - September 4 at 11:59 AM |
| Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 6 at 11:22 PM |
| Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
finance.yahoo.com - August 6 at 6:22 PM |
| Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study
finance.yahoo.com - August 5 at 9:23 AM |
| Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - August 1 at 6:24 PM |
| Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?
finance.yahoo.com - July 4 at 9:36 AM |
 | DNLI Crosses Above Key Moving Average Level
www.nasdaq.com - June 20 at 6:09 PM |
| Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer
seekingalpha.com - June 12 at 12:44 PM |
| Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
finance.yahoo.com - June 12 at 12:44 PM |
| Denali's DNL310 nabs accelerated review status in U.S. for MPS II
seekingalpha.com - June 11 at 5:44 PM |
| Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
finance.yahoo.com - June 11 at 10:22 AM |
| Notable Two Hundred Day Moving Average Cross - DNLI
www.nasdaq.com - May 30 at 9:42 AM |
| Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 9 at 9:40 AM |
| Denali Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 8 at 6:26 PM |
| Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - May 3 at 6:13 PM |
| Controversial Alzheimer's Disease theory could pinpoint new drug targets
finance.yahoo.com - May 1 at 6:12 PM |
| Here’s What Hedge Funds Think About Denali Therapeutics Inc. (DNLI)
finance.yahoo.com - April 30 at 5:52 PM |
| 3 Biotech Stocks That Doubled After Hitting Bottom in 2018
finance.yahoo.com - April 10 at 11:46 AM |
 | Denali Therapeutics - On The Move
www.finanznachrichten.de - April 4 at 9:45 AM |
| Did Denali Therapeutics's (NASDAQ:DNLI) Share Price Deserve to Gain 26%?
finance.yahoo.com - April 2 at 5:51 PM |
| Interesting DNLI Put And Call Options For May 17th
www.nasdaq.com - March 21 at 6:10 PM |
| Denali Therapeutics Inc. (DNLI)
finance.yahoo.com - March 14 at 10:04 AM |
 | 48 Stocks Moving In Wednesday's Mid-Day Session - Benzinga
www.benzinga.com - March 13 at 5:47 PM |
| Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates - Nasdaq
www.nasdaq.com - March 12 at 10:34 PM |
 | Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates
www.zacks.com - March 12 at 10:58 AM |
| Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
finance.yahoo.com - March 12 at 10:58 AM |
| Commit To Purchase Denali Therapeutics At $20, Earn 25.4% Annualized Using Options
www.nasdaq.com - February 21 at 5:15 PM |
| Early-stage study of Denali's Alzheimer's candidate DNL747 underway; shares up 1% premarket
seekingalpha.com - February 15 at 10:12 AM |
| Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
finance.yahoo.com - February 15 at 10:12 AM |
| Sanofi delivers 2018 business EPS growth of 5.1% at CER
feeds.benzinga.com - February 7 at 2:47 AM |
 | Genentech kills big drug study in early Alzheimer's patients
www.bizjournals.com - January 30 at 5:40 PM |
 | Denali Therapeutics Inc
www.bloomberg.com - January 30 at 9:44 AM |
 | Denali Therapeutics Inc.
www.barrons.com - January 29 at 5:09 PM |
| Denali teams up with Sirion in gene therapies
seekingalpha.com - January 9 at 9:46 AM |
| Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
finance.yahoo.com - January 8 at 9:38 AM |
| Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
finance.yahoo.com - December 10 at 9:22 AM |
| The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
finance.yahoo.com - December 8 at 4:26 PM |
| Commit To Buy Denali Therapeutics At $15, Earn 10.9% Annualized Using Options
www.nasdaq.com - November 21 at 4:24 PM |
| Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
finance.yahoo.com - November 20 at 9:17 AM |
| Denali Therapeutics Breaks Above 200-Day Moving Average - Bullish for DNLI
www.nasdaq.com - November 15 at 4:24 PM |
| Benzinga's Top Upgrades, Downgrades For November 15, 2018
www.benzinga.com - November 15 at 9:22 AM |
 | Form 3 Denali Therapeutics Inc. For: Nov 06 Filed by: Cook Jennifer E.
www.streetinsider.com - November 10 at 9:30 AM |
| Denali Therapeutics (DNLI) Announces Jennifer Cook to Board
www.streetinsider.com - November 10 at 9:30 AM |
